Update on prescribing of antiviral medicines

Update on prescribing of antiviral medicines

0 개 747 노영례

378c3ed087b7ea07d2085063d961537a_1654061588_9843.png
 

Access to treatment for COVID-19 in the community has been widened, with dedicated pharmacists prescribers now able to prescribe antiviral medicines.

A notice was published in the Gazette this week, adding medicines for treating COVID-19 to the schedule that can be prescribed by a dedicated pharmacists prescriber.

This will mean some pharmacists will be able to prescribe antiviral medicines for treating COVID-19, instead of needing to wait to see another prescriber in the team.

The decision to enable pharmacists to prescribe a specific medicine is independent from Medsafe’s decision to approve a medicine for use or Pharmac’s decision to fund a medicine

Clinical Chief Advisor Andi Shirtcliffe said: “Increasing the range of prescribers will improve access to these medicines for a wider range of communities and get timely treatment to more of the people who are at risk of severe illness.”

Medicines added to the pharmacist prescriber medicine list include nirmatrelvir with ritonavir (Paxlovid™) and molnupiravir (Lagevrio®), which are already being prescribed by other prescribers in New Zealand.

Both these medicines can be taken orally at home and are for people who have been diagnosed with COVID-19, have symptoms, and are at a higher risk of hospitalisation including Māori and Pacific peoples, those with complex health needs, the elderly and unvaccinated populations, and people with disabilities.

The medicines were added to the pharmacist prescriber medicine list after consultation with the sector, including the Pharmacy Council, which ran between 22 April and 22 May. Of the submissions received, more than 90% agreed with the proposed additions to the schedule.

A summary of the consultation will be published on the Ministry’s website soon.


 


Additional information

Nine COVID-19 therapeutics have been added to the schedule for designated pharmacist prescribers.

Of these, four active ingredients have already been approved for use in New Zealand are included, covering three products.

These include:

  • Nirmatrelvir with ritonavir (Paxlovid™) and molnupiravir (Lagevrio®) – Both are five-day courses of tablets or capsules. They need to be taken within five days of a person first developing symptoms for COVID-19. These medicines are prescribed to people who have been diagnosed with COVID-19, have symptoms, and are at a higher risk of hospitalisation including Māori and Pacific peoples, those with complex health needs, the elderly and unvaccinated populations, and people with disabilities.
  • Casirivimab and imdevimab (Ronapreve) – A drug provided by an infusion or subcutaneous injection under the supervision of a healthcare professional, and is already available in New Zealand.  Ronapreve is prescribed for adults and adolescents with COVID-19 who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. Ronapreve is known to be effective against the Delta variant and research is now focusing on its effectiveness against the Omicron variant.  Medsafe will continue to evaluate that information when it becomes available. In addition, these unapproved medicines have also been added to the schedule.
  • Etesevimab, sotrovimab (Xevudy), ensovibep, cilgavimab, tixagevimab – Medsafe has not yet approved these medicines for use in New Zealand, therefore these cannot be prescribed, by pharmacists or other clinicians, at this stage. However, adding these medicines to schedule will help widen access to prescribers in the event these medicines are approved for use in New Zealand in the future.

More information about COVID treatments approved for use and under active consideration


출처 : 보건부 보도자료

STARS OF TV AND SYMPHONY ALIGN FOR CHILDREN’S…

댓글 0 | 조회 241 | 9일전
Howls of What's the time … 더보기

Housing recovery spreads to nearly 60% of NZ …

댓글 0 | 조회 278 | 2024.03.14
Property values rose in a… 더보기

Annual growth back in black despite flat Febr…

댓글 0 | 조회 333 | 2024.03.12
Property values are sligh… 더보기

No OCR change... for now

댓글 0 | 조회 668 | 2024.02.28
Today's decision by the R… 더보기

Construction cost growth continuing to cool

댓글 0 | 조회 272 | 2024.02.28
The average cost of build… 더보기

Property sale volumes remain erratic

댓글 0 | 조회 518 | 2024.02.20
High mortgage rates conti… 더보기

Home values continue to strengthen, slowly bu…

댓글 0 | 조회 635 | 2024.02.13
The housing market's slow… 더보기

Profitable resales rise for the first time in…

댓글 0 | 조회 563 | 2024.02.08
93.3% of property resales… 더보기

MetService launches push notifications for Ne…

댓글 0 | 조회 491 | 2024.01.25
From today 25 January, Ki… 더보기

Property market signs off 2023 on a strong no…

댓글 0 | 조회 441 | 2024.01.17
The CoreLogic House Price… 더보기

Heat comes out of the construction sector as …

댓글 0 | 조회 374 | 2024.01.11
As pressures on residenti… 더보기

What the shortened Brightline test means for …

댓글 0 | 조회 455 | 2023.12.21
Following the Government’… 더보기

Housing upturn broadens, but underwhelming 20…

댓글 0 | 조회 665 | 2023.12.20
TheCoreLogic NZ December … 더보기

Slow recovery to be continued in 2024

댓글 0 | 조회 496 | 2023.12.19
The housing market contin… 더보기

New Zealanders' Standard of Living in Freefal…

댓글 0 | 조회 904 | 2023.12.14
Responding to today’s rel… 더보기

A turning point for the NZ housing market

댓글 0 | 조회 605 | 2023.12.13
A 'year of two halves' ap… 더보기

10 things to know about mortgage debt right n…

댓글 0 | 조회 1,136 | 2023.12.06
The housing loan market h… 더보기

Home values rise 0.7% in November

댓글 0 | 조회 1,104 | 2023.12.01
Hot on the heels of Octob… 더보기

Mayor’s proposal to make public transport fas…

댓글 0 | 조회 399 | 2023.11.30
Mayor Wayne Brown is prop… 더보기

Cost of building a home increases by 4.9% ann…

댓글 0 | 조회 518 | 2023.11.30
The average cost of build… 더보기

An OCR decision of words not actions

댓글 0 | 조회 506 | 2023.11.29
By Kelvin Davidson, Chief… 더보기

New Zealand rents surge 6.1% in the past year

댓글 0 | 조회 1,103 | 2023.11.23
Rental growth is running … 더보기

New Zealand's Most Beautiful Towns and Cities…

댓글 0 | 조회 878 | 2023.11.10
Iconic Kiwi charity Keep … 더보기

House prices begin to rise, but recovery set …

댓글 0 | 조회 939 | 2023.11.01
fter remaining flat in Se… 더보기

More than 67,000 Kiwis take part in New Zeala…

댓글 0 | 조회 1,652 | 2023.10.26
Iconic Kiwi charity Keep … 더보기